Biological Effects of Quercetin in COPD

Status unconfirmed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

This study determines whether quercetin supplementation reduces the inflammation and oxidative stress markers in patients with chronic obstructive pulmonary disease. It is small study with 8 subjects receive quercetin 2000 mg/day and 4 subjects receive placebo.

Key facts

Study ID

NCT03989271

Run by

Temple University

People needed

29

Starts

2019-10-01

Expected to finish

2025-07-01

Last updated by the study team

2023-08-16

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with COPD, 40 - 80 yrs of age
• Post-bronchodilator forced expiratory volume (FEV)1/forced vital capacity (FVC) ratio 0.7, FEV1% predicted between 40 to 70
• Both active and ex-smokers with at least 10 pack-years history of smoking
• COPD patients taking H2 antagonists, loperamide or loratadine and willing to stop during the study period

You may not qualify if…

• Known allergy/sensitivity to quercetin
• Subjects with primary current diagnosis of asthma
• Upper respiratory tract infection within two weeks of the screening visit
• Acute bacterial infection requiring antibiotics within two weeks of screening
• Emergency treatment or hospitalization within one month of screening for any reasons
• Unwillingness to stop flavonoid supplementation
• Dietary intake exceeding or averaging 150 mg quercetin daily as assessed by Bioflavonoid Food and Supplement Screener
• Daily warfarin or cyclosporine (Neoral, Sandimmune)
• Subjects taking H2 antagonists (cimetidine, ranitidine), loperamide (Imodium) or loratadine and not willing to stop during study period
• Lung cancer history or undergoing chemo- or radiation therapy
• Inflammatory bowel disease
• Subjects with no detectable levels of inflammatory CRP or SP-D in blood and/or IL-
• 1β or 8-isoprostane in the exhaled breath condensate
• Women of child-bearing age and unwilling to take pregnancy test
• Child-bearing age, who are unwilling to use adequate contraception or abstain during the course of the study.
• Pregnant or lactating mothers

Where it is running

• Nathaniel Marchetti — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.